<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21774">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003612</url>
  </required_header>
  <id_info>
    <org_study_id>20120310</org_study_id>
    <nct_id>NCT02003612</nct_id>
  </id_info>
  <brief_title>Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia</brief_title>
  <official_title>An Analysis of Historical Data on Hematological Remission and Survival Among Adult Patients With Relapsed / Refractory B-Precursor Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>Germany: Ethic commission of the faculty of medicine, University of Frankfurt</authority>
    <authority>France: CCTIRS (comité consultative sur le traitement de l'information en matière de recherche dans le domaine de la santé)</authority>
    <authority>France: CNIL (Commission Nationale de L'informatique et Liberté)</authority>
    <authority>France: CNOM (Conseil National de L'ordre des médecins)</authority>
    <authority>Spain: Ethics Committee: Comité Ético de Investigación Clínica del Hospital Universitario Germans Trías i Pujol</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective analysis of historical data looking at hematological remission and survival
      in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective observational study reviewing historical survival data (hematological
      remission and survival) for adult patients who have either relapsed or refractory
      B-precursor acute lymphoblastic leukemia. Data are aggregated across multiple countries and
      study sites in the EU and US
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>hematological complete remission</measure>
    <time_frame>Approx 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the proportion of patients in hematological complete remission (CR) for R/R Philadelphia chromosome negative (Ph-) B-precursor ALL patients following relapse or salvage treatment, excluding patients with a first remission duration of &gt;12 months in first salvage (ie, patients with late relapse in first salvage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Approx 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>to estimate overall survival for relapsed / refractory philadelphia negative B-precursor acute lymphoblastic leukemia patients following salvage treatment, excluding patients with late relapse in first salvage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of complete remission</measure>
    <time_frame>Approx 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>to estimate the duration of complete remission for philadelphia negative patients following treatment for relapsed / refractory B-precursor acute lymphoblastic leukemia, excluding patients with late relapse in first salvage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients receiving allogeneic hematological stem cell transplantation</measure>
    <time_frame>Approx 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>estimate the proportion of patients receiving allogeneic hematological stem cell transplantation for philadelphia negative patients following treatment for relapsed / refractory B-precursor acute lymphoblastic leukemia excluding those with late relapse in first salvage</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2373</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <description>All subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable - observational study</intervention_name>
    <description>No intervention exists as this is a retrospective observational study</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with relapsed / refractory B-precursor acute lymphoblastic leukemia identified in
        study group databases from multiple sites in EU and US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with relapsed / refractory B-precursor acute lymphoblastic leukemia

          -  age 15 or older at time of de novo (initial) diagnosis of acute lymphoblastic
             leukemia

          -  initial diagnosis of acute lymphoblastic leukemia in the year 1990 or later

          -  No CNS involvement at relapse

          -  No isolated extramedullary relapse

          -  Other inclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venezia</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <state>Cataluña</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
